{
    "clinical_study": {
        "@rank": "38775", 
        "arm_group": {
            "arm_group_label": "Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence\n      of breast cancer.\n\n      PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who\n      are at high risk for breast cancer recurrence."
        }, 
        "brief_title": "Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine whether immunization with multiple antigens comprising GM2, Globo-H, Lewis y,\n           TF(c), sTn(c), Tn(c), and glycosylated MUC-1 32(aa) conjugated to keyhole limpet\n           hemocyanin plus QS21 induces an antibody response against these individual antigens and\n           breast cancer cells expressing these antigens in patients at high risk for breast\n           cancer recurrence.\n\n        -  Determine the toxic effects of this regimen in these patients.\n\n      OUTLINE: Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate\n      vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2-3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of breast cancer at high risk for recurrence, defined by one of the\n             following:\n\n               -  Stage IV that is free of all known disease after eradication by surgery,\n                  radiotherapy, or chemotherapy\n\n                    -  May or may not have elevated CA 15-3 or CEA levels\n\n               -  Stage I, II, or III previously treated with adjuvant chemotherapy and clinically\n                  free of identifiable disease, but have rising CA 15-3 or CEA levels\n\n                    -  Rising CA 15-3 and CEA defined as a prior normal level increased on 2\n                       consecutive occasions at least 2 weeks apart\n\n                         -  For patients with a significant history of smoking who have a\n                            chronically elevated CEA (less than 15), CEA must be increased at\n                            least 1.5 times the uppermost chronic value on 2 consecutive occasions\n                            at least 2 weeks apart\n\n               -  Stage III and completed adjuvant therapy no more than 24 months ago\n\n               -  Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection\n                  or modified radical mastectomy\n\n               -  Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection\n\n               -  Stage II with at least 4 positive axillary nodes and completed adjuvant therapy\n                  no more than 24 months ago\n\n               -  Stage IV that is stable on hormonal therapy\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Male or female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 80-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Lymphocyte count at least 500/mm^3\n\n          -  WBC at least 3,000/mm^3\n\n        Hepatic:\n\n          -  AST no greater than 1.5 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase no greater than 1.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Cardiovascular:\n\n          -  No clinically significant New York Heart Association class III or IV cardiac disease\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No prior seafood allergy\n\n          -  No known prior immunodeficiency or autoimmune disease\n\n          -  No other active cancer except basal cell or squamous cell skin cancer\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 6 weeks since prior immunotherapy\n\n          -  No prior vaccine with any of the antigens in this study\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior chemotherapy\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior surgery\n\n          -  Concurrent surgery for local recurrence allowed if patient remains disease free"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030823", 
            "org_study_id": "01-019", 
            "secondary_id": [
                "MSKCC-01019", 
                "NCI-H01-0084"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Vaccine", 
                "intervention_name": "Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Vaccine", 
                "intervention_name": "QS21", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adjuvants, Immunologic", 
                "Keyhole-limpet hemocyanin", 
                "QS 21"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage I breast cancer", 
            "stage II breast cancer", 
            "stage IV breast cancer", 
            "stage IIIA breast cancer", 
            "recurrent breast cancer", 
            "stage IIIB breast cancer", 
            "stage IIIC breast cancer", 
            "male breast cancer"
        ], 
        "lastchanged_date": "March 1, 2013", 
        "link": [
            {
                "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
                "url": "http://cancer.gov/clinicaltrials/MSKCC-01019"
            }, 
            {
                "description": "Memorial Sloan-Kettering Cancer Center", 
                "url": "http://www.mskcc.org/"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Teresa Ann Gilewski, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "against these individual antigens and breast cancer cells expressing these antigens in patients at high risk for breast cancer recurrence.", 
            "measure": "Determine whether immunization with multiple antigens comprising GM2, Globo-H, Lewis y, TF(c), sTn(c), Tn(c), and glycosylated MUC-1 32(aa) conjugated to keyhole limpet hemocyanin plus QS21 induces an antibody response", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030823"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "citation": "Armstrong JL, Ragupathi G, Powell S, et al.: Preliminary data of vaccination of high risk breast cancer (BC) patients (pts) with a heptavalent antigen: keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-675, 2003."
        }, 
        "secondary_outcome": {
            "measure": "Determine the toxic effects of this regimen in these patients", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}